AskBio Announces First Patient Randomized in Phase 1 Trial of AB-1005 (AAV2-GDNF) Gene Therapy for Multiple System Atrophy-Parkinsonian Type (MSA-P)

Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels in the brain for the treatment ...

Related Keywords

United States ,Edinburgh ,City Of ,United Kingdom ,Olmsted County ,Minnesota ,Research Triangle Park ,North Carolina ,Michigan ,Scotland ,Philipm Fortier ,Nicolasm Phielipp ,Krystof Bankiewicz ,Brain Neurotherapy Bio Inc ,Linkedin ,European Study Group On Atypical Parkinsonisms ,University Of California Irvine ,Quest Research Institute ,Bayer Ag ,Asklepios Biopharmaceutical Inc ,Drug Administration ,Ohio State University Wexner Medical Center ,Trademark Office ,Asklepios Biopharmaceutical ,Executive Director ,California Irvine ,Scientific Chair ,United States Food ,United States Patent ,Multiple System ,Accessed November ,European Study Group ,Auton Res ,